Previous 10 | Next 10 |
Gainers: Sidus Space (SIDU) +94%. Evoke Pharma (EVOK) +50%. Visionary Education Technology Holdings (VEDU) +37%. Heliogen (HLGN) +27%. Ribbon Communications (RBBN) +25%. Digital World Acquisition (DWACW) +22%. Wheels Up Experience (UP) +21%. Austin Gold (AUST) +21%. AeroClean Technologies (AE...
Gainers: Evoke Pharma EVOK +52%. Zynerba Pharmaceuticals (ZYNE) +18%. LifeMD (LFMD) +13%. Vivos Therapeutics (VVOS) +12%. ACADIA Pharmaceuticals ACAD +11%. Losers: 180 Life Sciences (ATNF) -31%. Belite Bio (BLTE) -19%. VectivBio VECT -14%...
VectivBio Holding (NASDAQ:VECT) has priced a follow-on public offering of 5.72M ordinary shares at a price of $5.25/share for aggregate gross proceeds of ~$30M. Underwriters are granted a 30-day option to purchase up to an additional 857,250 ordinary shares at the public offering price. Offer...
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the pricing of a follow-on public offeri...
Clinical-stage biopharmaceutical company VectivBio Holding launched a follow-on public offering of ordinary shares and agreed to sell ~$20M worth ordinary shares to Forbion Growth Opportunities Fund II Coöperatief U.A. in a private placement transaction. For the public offering, size not...
BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the launch of a follow-on public offerin...
BASEL, Switzerland, June 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2022 Annual Genera...
– Interim proof-of-concept data anticipated from STARGAZE in H1 2023 – First-in-class regenerative, non-immunosuppressive approach to treating acute Graft-versus-Host Disease – Second clinical indication under evaluation for apraglutide, demonstratin...
Gainers: Palo Alto Networks (PANW) +11%. Bioceres Crop Solutions (BIOX) +7%. VectivBio Holding AG (VECT) +7%. Aveanna Healthcare Holdings (AVAH) +6%. Fate Therapeutics (FATE) +5%. Losers: Foghorn Therapeutics (FHTX) -26%. Ross Stores (ROST) -23%. Atara Biotherapeutics (A...
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founde...
News, Short Squeeze, Breakout and More Instantly...
Simplicity Esports (WINR) is expected to report for quarter end 2024-02-29 BankUnited Inc. (BKU) is expected to report $0.62 for Q1 2024 Winmark Corporation (WINA) is expected to report for Q1 2024 SL Green Realty Corp (SLG) is expected to report $2.17 for Q1 2024 Union Bankshares...
VectivBio Holding AG (VECT) is expected to report for quarter end 2023-12-31
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastroint...